D69.4
Other primary thrombocytopenia
Clinical Classification Guidelines
Excludes Type 1
- transient neonatal thrombocytopenia (P61.0)
- Wiskott-Aldrich syndrome (D82.0)
Medical Intelligence & Overview
Other Primary Thrombocytopenia, classified under ICD-10 code D69.4, refers to a group of disorders characterized by a reduced number of platelets in the blood. Platelets are essential for blood clotting and preventing excessive bleeding. When platelet levels are abnormally low, it can lead to increased bleeding risks, bruising, and other health concerns. This condition is considered 'primary' because it originates within the bone marrow, where blood cells are produced, rather than being caused by external factors or other diseases.
Causes & Symptoms
Clinical Causes: Autoimmune responses where the body's immune system mistakenly destroys platelets. Genetic factors or inherited conditions affecting platelet production. Bone marrow disorders that impair platelet synthesis. Certain medications that can suppress bone marrow function. Unknown or idiopathic origins in many cases.
Key Symptoms: Easy or excessive bruising Petachiae, which are tiny reddish or purple spots on the skin Prolonged bleeding from cuts Frequent nosebleeds Bleeding gums Unexplained fatigue or weakness (due to anemia or blood loss) Heavy menstrual periods
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves a combination of blood tests and medical evaluations. Key diagnostic steps include: - Complete blood count (CBC) to assess platelet levels - Bone marrow biopsy to examine marrow cell production - Tests for other autoimmune or infectious causes - Evaluation of medication history to rule out drug-induced thrombocytopenia Additional tests may be performed to rule out secondary causes or related conditions.
Treatment Protocols: Treatment strategies depend on the severity of the condition, underlying cause, and patient-specific factors. Common approaches include: - Observation for mild cases with no significant bleeding - Corticosteroids to suppress immune response in autoimmune cases - Intravenous immunoglobulin (IVIG) for transient platelet increase - Medications that stimulate platelet production - Avoidance of medications or substances that may suppress marrow function - In severe or refractory cases, options such as splenectomy (removal of the spleen) or other therapies may be considered. Regular monitoring and consultation with healthcare providers are essential to manage the condition effectively.
Clinical Advice & FAQs
Billing Guidance
Is D69.4 a billable ICD-10 code?
Yes, D69.4 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D69.4?
Clinical documentation must specify the nature of Other primary thrombocytopenia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference